Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab

References

• Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014;53:1664–8.
   PubMed Web of Science ®Google Scholar
• Kim HL, Lee MY, Park SY, Park SK, Byun JH, Kwon S, et al. Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach. Arch Pharm Res. 2014;37:662–70.
   PubMed Web of Science ®Google Scholar
• Hirabara S, Takahashi N, Fukaya N, Miyake H, Yabe Y, Kaneka A, et al. Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies. Clin Rheumatol. 2014;33:1247–54.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–23.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, et al. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Mod Rheumatol. 2014;24:399–404.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K. Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12–19.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016;208426. doi: 10.1136/annrheumdis-2015-208426.
   Web of Science ®Google Scholar
• Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, et al. Long-term safety and efficacy of subcutaneous tocilizumab monotherapy: results from the 2-year open-label extension of the MUSASHI study. J Rheumatol. 2015;42:799–809.
   PubMed Web of Science ®Google Scholar
• Matsuno H. Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts. Mod Rheumatol. 2015;25:38–42.
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541–50.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, et al. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumor necrosis factor therapy: post hoc analyses from the GO-AFTER study. Ann Rheum Dis. 2014;73:1811–18.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35:745–57.
   PubMed Web of Science ®Google Scholar
• Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114–21.
   PubMed Web of Science ®Google Scholar
• Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015;29:241–58.
   PubMed Web of Science ®Google Scholar
• Romão VC, Santos MJ, Polido-Pereira J, Duarte C, Nero P, Miguel C, et al. Comparative effectiveness of tocilizumab and TNF inhibitors in rheumatoid arthritis patients: data from the rheumatic diseases Portuguese register, Reuma.pt. Biomed Res Int. 2015;279890. doi: 10.1155/2015/279890.
   PubMed Web of Science ®Google Scholar
• Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2015;74:890–6.
   PubMed Web of Science ®Google Scholar
• Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis. 2012;71:1303–8.
   PubMed Web of Science ®Google Scholar